HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on ...

As of September 30, 2024, Fortress' consolidated cash and cash equivalents totaled $58.9 million, compared to $76.2 million ...

Good afternoon and welcome to today's conference call for Omeros Corporation. (Operator Instructions) Please be advised that this call is being recorded at the company's request and a replay will be ...

Shares of Omeros touched a 52-week high, a day after the company said it could resubmit its biologics license application for narsoplimab to the Food and Drug Administration. In Thursday afternoon ...

The approval marks the first time gene therapy will be available to treat patients with aromatic I-amino acid decarboxylase ...

ANX005 in Guillain-Barré syndrome (GBS): First-in-kind monoclonal antibody designed to block C1q and the entire classical complement pathway in both the body and the brain has the potential to be the ...

Following strong treatment response data for Adaptimmune’s lete-cel, the biotech is planning to initiate a rolling BLA ...

Reports Q3 revenue $0 vs. $0 last year. “With the acceptance of our Biologics License Application resubmission for pz-cel, we are ramping up our commercial readiness efforts, especially with respect ...

As described in previous updates, we have been working closely with FDA regarding the anticipated resubmission of our Biologics License Application, or BLA for narsoplimab in hematopoietic stem cell ...

following the approval of ATSN-101’s Biologics License Application (BLA), the company will retain all rights, title, and ...

AstraZeneca’s earnings were boosted by its oncology, cardiovascular, respiratory and immunology (R&I), and rare disease ...